The reformulation of Amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis

Expert Opinion on Drug Delivery

Volumn 6, Issue 3, 2009, Pages 271-284

  Thornton, Sheila J ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amphotericin B; Antifungal; Leishmaniasis; Oral formulation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY GLUCONATE; CARBENOXOLONE; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; POSACONAZOLE; SITAMAQUINE; STIBOGLUCONATE SODIUM; VORICONAZOLE; ANTIFUNGAL AGENT; ANTITRYPANOSOMAL AGENT;

ACUTE PANCREATITIS; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; METHEMOGLOBINEMIA; NEPHROTOXICITY; NONHUMAN; REVIEW; SYSTEMIC MYCOSIS; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; ANIMAL; CHEMISTRY; MYCOSIS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; HUMANS; LEISHMANIASIS, VISCERAL; MYCOSES; TRYPANOCIDAL AGENTS;

EID: 66149157922     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902802861     Document Type: Review

References (73)

1. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005;56(Suppl 1):i5-11 (Pubitemid 41236084)
2. Mathew BP, Nath M. Recent approaches to antifungal therapy for invasive mycoses. ChemMedChem 2009. [Epub ahead of print] DOI: 10.0002/cmdc.200800353
3. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 2006;123(3):345-352 (Pubitemid 43905574)
4. Le Pape P. Development of new antileishmanial drugs-current knowledge and future prospects. J Enzyme Inhib Med Chem 2008;23(5):708-718
5. Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005;5(12):763-774
6. Thakur CP, Pandey AK, Sinha GP, et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996;90(3):319-322 (Pubitemid 26188890)
7. Thakur CP, Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate,as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 2004;98(2):129-138 (Pubitemid 38388881)
8. Donovick R, Gold W, Pagano JF, Stout HA. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiot Annu 1955-1956;3:579-586
9. Stiller ET, Vandeputte J, Wachtel JL. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. II. The isolation and properties of the crystalline amphotericins. Antibiot Annu 1955-1956;3:587-591
10. Zygmunt WA, Tavormina PA. Steroid interference with antifungal activity of polyene antibiotics. Appl Microbiol 1966;14(6):865-869
11. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta 1986;864(3-4):257-304
12. Ng AW, Wasan KM, Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 2003;6(1):67-83 (Pubitemid 37207242)
13. Jambor WP, Steinberg BA, Suydam LO. Amphotericins A and B: two new antifungal antibiotics possessing high activity against deep-seated and superficial mycoses. Antibiot Annu 1955-1956;3:574-578
14. Oura M, Sternberg TH, Wright ET. A new antifungal antibiotic, amphotericin B. Antibiot Annu 1955-1956;3:566-573
15. Bartner E, Zinnes H, Moe RA, Kulesza JS. Studies on a new solubilized preparation of amphotericin B. Antibiot Annu 1957-1958;5:53-58
16. Utz JP, Louria DB, Feder N, et al. A report of clinical studieson the use of amphotericin in patients with systemic fungal diseases. Antibiot Annu 1957-1958;5:65-70
17. Littman ML, Horowitz PL, Swadey JG. Coccidioidomycosis and its treatment with amphotericin B. Am J Med 1958;24(4):568-592
18. Kravetz HM, Andriole VT, Huber MA, Utz JP. Oral administration of solubilized amphotericin B. N Engl J Med 1961;265:183-184
19. Louria DB. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiotic Med Clin Ther 1958;5(5):295-301
20. Ghosh BK, Ghosh A. The effects of antibiotics on Leishmania donovani. Dermatol Int 1967;6(3):154-160
21. Robbie G, Wu TC, Chiou WL. Poor and unusually prolonged oral absorption of amphotericin B inrats. Pharm Res 1999;16(3):455-458 (Pubitemid 29162106)
22. Dutcher JD. The discovery and development of amphotericin B. Dis Chest 1968;54(Suppl 1):296-298
23. Singh RK, Pandey HP, Sundar S. Visceral leishmaniasis (kala-azar): challenges ahead. Indian J Med Res 2006;123(3):331-344 (Pubitemid 43905573)
24. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007;5(11):873-882
25. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002;2(11):845-858 (Pubitemid 37328707)
26. Kamhawi S. Phlebotomine sand flies and Leishmania parasites: friends or foes? Trends Parasitol 2006;22(9):439-445
27. Bates PA. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int J Parasitol 2007;37(10):1097-1106 (Pubitemid 47042030)
28. Herwaldt BL. Leishmaniasis. Lancet 1999;354(9185):1191-1199
29. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2(8):494-501 (Pubitemid 34826855)
30. Santos DO, Coutinho CE, Madeira MF, et al. Leishmaniasis treatment-a challenge that remains: a review. Parasitol Res 2008;103(1):1-10
31. Thakur CP, Narayan S, Ranjan A. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 2004;120(3):166-172 (Pubitemid 39406044)
32. Papadopoulou B, Kundig C, Singh A, Ouellette M. Drug resistance in Leishmania: similarities and differences to other organisms. Drug Resist Updat 1998;1(4):266-278
33. Ashutosh, Sundar S, Goyal N. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 2007;56(Pt 2):143-153 (Pubitemid 46302715)
34. Das VN, Ranjan A, Sinha AN, et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India 2001;49:609-613 (Pubitemid 33702117)
35. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006;123(3):399-410 (Pubitemid 43905578)
36. Swenson CE, Perkins WR, Roberts P, et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother 1998;42(4):767-771
37. Leon C, Taylor R, Bartlett KH, Wasan KM. Effect of heat-treatment and the role of phospholipases on Fungizone-induced cytotoxicity within human kidney proximal tubular (HK-2) cells and Aspergillus fumigatus. Int J Pharm 2005;298(1):211-218 (Pubitemid 40828342)
38. Mullen AB, Baillie AJ, Carter KC. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother 1998;42(10):2722-2725 (Pubitemid 28462922)
39. Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008;47(8):1000-1006
40. Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs 2008;17(5):787-794 (Pubitemid 351843621)
41. Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for Visceralleishmaniasis in India. N Engl J Med 2007;356(25):2571-2581
42. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987;36(16):2633-2636 (Pubitemid 17102920)
43. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996;38(6):1041-1047 (Pubitemid 27073283)
44. Le Fichoux Y, Rousseau D, Ferrua B, et al. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 1998;42(3):654-658 (Pubitemid 28114823)
45. Berman JJ. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol 2008;4(9):1209-1216
46. Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007;196(4):591-598 (Pubitemid 47206107)
47. Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, et al. Mechanismsof experimental resistance of leishmania to miltefosine: implications for clinical use. Drug Resist Updat 2006;9(1-2):26-39 (Pubitemid 43928805)
48. Seifert K, Matu S, Javier Perez-Victoria F, et al. Characterisation of leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 2003;22(4):380-387 (Pubitemid 37163727)
49. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007;3(5):733-740 (Pubitemid 350162073)
50. Dujardin JC, Campino L, Canavate C, et al. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis 2008;14(7):1013-1018 (Pubitemid 351920428)
51. Jha TK, Sundar S, Thakur CP, et al. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 2005;73(6):1005-1011 (Pubitemid 43038244)
52. Wasunna MK, Rashid JR, Mbui J, et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005;73(5):871-876 (Pubitemid 41688461)
53. Bories C, Cojean S, Huteau F, Loiseau PM. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of leishmania donovani. Biomed Pharmacother 2008;62(3):164-167
54. Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 2008;36(4):296-313
55. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14(Suppl 1):S161-9
56. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992;15(1):21-34
57. Groll AH, Walsh TJ. Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly 2002;132(23-24):303-311 (Pubitemid 35033785)
58. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents :pharmacokinetics, safety and efficacy. Drugs 2004;64(18):1997-2020 (Pubitemid 39280370)
59. Urcuyo FG, Zaias N. Oral ketoconazole in the treatment of leishmaniasis. Int J Dermatol 1982;21(7):414-416 (Pubitemid 12062639)
60. Wasan KM, Sivak O, Rosland M, et al. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus. J Pharm Sci 2007;96(7):1737-1747 (Pubitemid 47122952)
61. Golenser J, Domb A. New formulations and derivatives of amphotericin B for treatment of leishmaniasis. Mini Rev Med Chem 2006;6(2):153-162
62. Kayser O, Olbrich C, Yardley V, et al. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003;254(1):73-75 (Pubitemid 36259814)
63. Amarji B, Raghuwanshi D, Vyas SP, Kanaujia P. Lipid Nano Spheres (LNSs) for enhanced oral bioavailability of amphotericin B: development and characterization. J Biomed Nanotechnol 2007;3(3):264-269
64. Italia JL, Yahya MM, Singh D, Ravi Kumar MN. Biodegradable nanoparticles improve oral bioavailability of Amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone(R). Pharm Res 2009. [EPub ahead of Print] DOI: 10.1007/s11095-009-9841-9842
65. Zarif L, Mannino RJ. Cochleates. Lipid-based vehicles for gene deliveryconcept, achievements and future development. Adv Exp Med Biol 2000;465:83-93 (Pubitemid 32193326)
66. Zarif L, Graybill JR, Perlin D, et al. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 2000;44(6):1463-1469 (Pubitemid 30340780)
67. Santangelo R, Paderu P, Delmas G, et al. Efficacy of oral cochleate¬amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother 2000;44(9):2356-2360 (Pubitemid 30650879)
68. Delmas G, Park S, Chen ZW, et al. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 2002;46(8):2704-2707 (Pubitemid 34793493)
69. Sachs-Barrable K, Lee SD, Wasan EK, et al. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev 2008;60(6):692-701
70. Wasan EK, Bartlett K, Gershkovich P, et al. Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus Fumigatus or Candida Albicans. 2009. [EPub ahead of Print]. DOI 10.1016/j.ijpharm.2009.01.003
71. Lennartz MR. Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis. Int J Biochem Cell Biol 1999;31(3-4):415-430 (Pubitemid 29112903)
72. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3(8):673-683 (Pubitemid 39173508)
73. Wasan KM, Brocks DR, Lee SD, et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov 2008;7(1):84-99.